The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an […]
Category: FDA
Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US
Brekiya is now the first DHE auto-injector to be approved by the regulator
More than 37 million adults in the US are affected by migraine
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations